Golden Biotech Presents at BIO Asia Taiwan-Creating the New Treatment Paradigm for Pancreatic Cancer
Exhibitor: GOLDEN BIOTECHNOLOGY CORP.
Date: 2024-07-06
Booth No.: L318
Golden Biotech Presents at BIO Asia Taiwan- "Creating the New Treatment Paradigm for Pancreatic Cancer"
Golden Biotechnology Corp. (GBC, GoldenBiotech, TPEx 4132), an advanced biopharmaceutical drug company, dedicating to bringing innovation and hope to patients with High Unmet Medical Needs. It's lead drug, Antroquinonol, an NCE with multi-functions and has completed many Phase 2 trials of treating the NSCLC, AML, Pancreatic Cancer and COVID-19. The Phase 2 trial results for the first-line treatment of metastatic pancreatic cancer showed significantly longer overall survival (mOS), and high safety profile in decreasing the hematologic adverse events than those from the trials of standard therapies. It has received the ODD (Orphan Drug Designation) from the FDA for treating AML, Pancreatic Cancer, and HCC, as well as the ODD for treating Pancreatic Cancer from the EU.
Join us at BIO Asia Taiwan 2024 and discover the latest breakthrough in our clinical trials for metastatic pancreatic cancer and other indications.
GoldenBiotech welcomes the inquiries and discussions from the partners for all the possible cooperation.
During the 2024 BIO Asia Taiwan, Golden Biotech will present at the “Company Presentation” section, also hold the following seminar:
Topic: "Insights into the Phase 2 Metastatic Pancreatic Cancer Study (Antroquinonol + Nab-Paclitaxel+ Gemcitabine)”
Speakers: Boon-Kean Choy / General Manager and Dr. Penny Chen, MD / Medical Director
Time: 7/26 (Fr.), 11:30-12:20
Place: Room 506, Hall 1, 5th Fl., Taipei Nangang Exhibition Hall
Registration:
More Exhibitor's Press Release
- Taiwan’s Regenerative Medicine Acts passed, MYCENAX CDMO Services Are Ready! MYCENAX BIOTECH INC. / 2024-07-08
- Registration Today! 2024 BIO Asia Taiwan. Golden Biotech Seminar Registration GOLDEN BIOTECHNOLOGY CORP. / 2024-07-06
- EffPha meets you at BIO Asia- Taiwan Exhibition 2024 EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- EffPha – An expert-based CRO for your drug development EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- Featured Product: Saltonase, the Versatile Nuclease - Salt Tolerant and Easier Purification QIAGEN N.V. / 2024-07-05
- Vega Preclinical Ultrasound System J & H TECHNOLOGY CO., LTD. / 2024-07-05
- MYCENAX，YOUR BEST PARTNER FOR BIOLOGICS DEVELOPMENT MYCENAX BIOTECH INC. / 2024-07-04
- Bora Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility BORA PHARMACEUTICALS CO., LTD. / 2024-07-03
- Application and Market Development of Foods with Functional Claims in Japan GREENLINK BIOTECH INC. / 2024-07-03
- Featured Product: QIAGEN Beverly Single-Tube Enzymatic Fragmentation Library Preparation QIAGEN N.V. / 2024-07-02
- OEM by QIAGEN: Strategic Partnerships – A Partner that Extends Your Capabilities QIAGEN N.V. / 2024-07-02
- Comparison of Maglev Centrifugal Pump and Quaternary Diaphragm Pump Effects on mRNA encapsulated LNP LEVITRONIX GMBH TAIWAN BRANCH / 2024-07-01
- CRISPR cGMP gRNA Manufacturing MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- High-Throughput NGS Assistant - Feyond-F100 Fluorescence Microplate Reader MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- CLUBIO Life science solutions help universities upgrade equipments MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- EDA providing the most advanced and innovative optoelectronic medical equipment. EDA MEDICAL DEVICES TECHNOLOGY INC. / 2024-06-25
- TaiMed Biologics: Comprehensive CDMO Services from Bench to Market TAIMED BIOLOGICS INC. / 2024-06-25
- Marker X Decodes the Cancer Proteome Breaking the Limits of Early Cancer Screening Globally! MARKER EXPLORATION CORP. / 2024-06-21
- EffPha is the leading CRO for early phase oncology trials EFFICIENT PHARMA MANAGEMENT CORP. / 2024-06-20
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services FUJIFILM CORPORATION / 2024-06-18
